Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.

  • Niagen Bioscience's Change in Receivables fell 6366.2% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 17298.16%. This contributed to the annual value of $1.3 million for FY2024, which is 15671.84% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Change in Receivables is -$1.2 million, which was down 6366.2% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Receivables registered a high of $3.8 million during Q4 2022, and its lowest value of -$2.7 million during Q2 2023.
  • Its 5-year average for Change in Receivables is $232368.4, with a median of $130000.0 in 2021.
  • Data for Niagen Bioscience's Change in Receivables shows a peak YoY increase of 280230.77% (in 2022) and a maximum YoY decrease of 25175.95% (in 2022) over the last 5 years.
  • Niagen Bioscience's Change in Receivables (Quarter) stood at $130000.0 in 2021, then soared by 2802.31% to $3.8 million in 2022, then plummeted by 109.22% to -$348000.0 in 2023, then plummeted by 84.48% to -$642000.0 in 2024, then crashed by 81.0% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, $2.7 million for Q2 2025, and -$2.0 million during Q1 2025.